Regulus
regulus.com
Actively hiring
Artificial Intelligence
Drone AI
Drones & UAVs
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
F2 Venture Capital
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
F2 Venture Capital Similar startupsby what they do, their industry and backers
The CDDS interceptor is an autonomous, kinetic counter drone designed to neutralize Group 1 and Group 2 Unmanned Aerial System (UAS)…
Fiducial develops autonomous counter-drone and defence software for detection, interception and navigation in contested environments.
SOLUTIONS. Drone First Responder (DFR) Automation & AI Disaster Response Private Security & Overwatch Medical Delivery OEM & Specialty…
Low Cost MISSILES Built for modern drone warfare .. Portable Kinetic Missile Interceptor System for Group 1 and Group 2 Threats.
Armory is a defence startup building the best counter drone systems to defend Bharat against modern threats. Join us!
SkySafe’s advanced drone detection system and airspace intelligence platform enables organizations to identify, track, analyze, and act on…
Overview
Regulus provides complete Counter-UAS solutions: detect, track, identify, and neutralize. From soft-kill GNSS spoofing to kinetic interception. Integrated with 10 leading defense vendors.
News
Regulus Therapeutics stock holds as clinical data drive valuation
Regulus Therapeutics stock traded at USD 0.44 on September 22, 2026. Its 52-week range spans USD 0.31 to USD 1.42, keeping trial progress central.
Read more
Report
The Sky Today onThursday, October 16: The Moon rises with Regulus
Our satellite shares the constellation Leo with the Lion's bright heart, Regulus, near the famous Sickle asterism.
Read more
Report
How to see the moon, Venus and the bright star Regulus in an ultraclose conjunction tomorrow
Watch the crescent moon, Venus and the bright star Regulus align in a rare predawn close conjunction tomorrow.
Read more
Report
Novartis to buy Regulus Therapeutics for as much as $1.7 billion
Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.
Read more
Report
Pro access
Upgrade to see all 12 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.